Science Explorer Back to mapMap
Discussion
Company · Kirkland · United States

ProteoTech (United States)

proteotech.comROR OpenAlex
Research works
10
▼ 100% vs 2018-21
Citations
53
5.5 per fractional work
Top-10% rate
0.5%
all institutions 10.0%
Open access
6%
world 40%
International
3%
world 18%
ProteoTech (United States)

Not ranked overall: ProteoTech (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does ProteoTech (United States) work in?

In all years, 57% of research at ProteoTech (United States) is in Health Sciences, 31% in Life Sciences. Its largest fields are Medicine (57%), Biochemistry, Genetics and Molecular Biology (18%), Neuroscience (10%). It does 1.6× the world's share of Health Sciences.

Health Sciences: 5 fractional works · 57.3% of its workMedicine: 5 fractional works · 57.3% of its workPhysiology: 3 fractional works · 32.1% of its workPharmacology: 2 fractional works · 17.5% of its workNeurology: 0 fractional works · 5.2% of its workRheumatology: 0 fractional works · 1.8% of its workImmunology and Allergy: 0 fractional works · 0.8% of its workLife Sciences: 3 fractional works · 30.9% of its workBiochemistry, Genetics and Molecular Biology: 2 fractional works · 18.5% of its workMolecular Biology: 1 fractional works · 14.8% of its workBiotechnology: 0 fractional works · 3.4% of its workBiochemistry: 0 fractional works · 0.2% of its workNeuroscience: 1 fractional works · 10.4% of its workCellular and Molecular Neuroscience: 1 fractional works · 7.0% of its workCognitive Neuroscience: 0 fractional works · 3.4% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 2.0% of its workPharmacology: 0 fractional works · 2.0% of its workPhysical Sciences: 1 fractional works · 11.8% of its workComputer Science: 1 fractional works · 8.3% of its workComputational Theory and Mathematics: 1 fractional works · 8.3% of its workChemistry: 0 fractional works · 1.8% of its workOrganic Chemistry: 0 fractional works · 1.8% of its workMaterials Science: 0 fractional works · 1.8% of its workBiomaterials: 0 fractional works · 1.8% of its workALL ITS WORKProteoTech(United States)10fractional works, all years
Life Sciences31%Physical Sciences12%Health Sciences57%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 7 fields, with their numbers
    1. Medicine557.3%
    1. Biochemistry, Genetics and Molecular Biology218.5%
    2. Neuroscience110.4%
    3. Pharmacology, Toxicology and Pharmaceutics02.0%
    1. Computer Science18.3%
    2. Chemistry01.8%
    3. Materials Science01.8%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

    Who are the top researchers at ProteoTech (United States)?

    Ranked on the quality score, Joel A. Cummings and Thomas P. Lake lead among researchers whose main affiliation is ProteoTech (United States).

    1. 1 Joel A. Cummings United States · #2,211,107 worldwide 666 citations · 27 works
    2. 2 Thomas P. Lake United States · #2,719,773 worldwide 345 citations · 36 works
    All ranked researchers at ProteoTech (United States)

    What are the most cited papers from ProteoTech (United States)?

    The most cited paper from ProteoTech (United States) is "The Amazon rain forest plant Uncaria tomentosa (cat’s claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques and tangles" (Alan D. Snow, Gerardo M. Castillo, Beth P. Nguyen et al., 2019), with 72 citations. Next come "Laminin inhibition of ?-amyloid protein (A?) fibrillogenesis and identification of an A? binding site localized to the globular domain repeats on the laminin a chain" (61) and "P3‐254: Exebryl‐1: A novel small molecule currently in human clinical trials as a disease‐modifying drug for the treatment of Alzheimer's disease" (19).

    Most cited papers
    #PaperReleasedCitations
    1 The Amazon rain forest plant Uncaria tomentosa (cat’s claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques and tangles Alan D. Snow, Gerardo M. Castillo, Beth P. Nguyen et al. · Scientific Reports Open access 6 Feb 2019 72
    2 Laminin inhibition of ?-amyloid protein (A?) fibrillogenesis and identification of an A? binding site localized to the globular domain repeats on the laminin a chain Gerardo M. Castillo, Widia Lukito, Elaine R. Peskind et al. · Journal of Neuroscience Research 2000 61
    3 P3‐254: Exebryl‐1: A novel small molecule currently in human clinical trials as a disease‐modifying drug for the treatment of Alzheimer's disease Alan D. Snow, Joel A. Cummings, Thomas P. Lake et al. · Alzheimer s & Dementia 25 Jun 2009 19
    4 P2‐529: Identification of Exebryl‐1® and other novel small molecules as tau protein aggregation inhibitors Qubai Hu, Judy A. Cam, Thomas P. Lake et al. · Alzheimer s & Dementia Jul 2011 5
    5 Measuring APP Carboxy-Terminal Fragments Luke Esposito · Methods in molecular biology Book chapter 2010 4
    All 14 most cited papers, with filters and sorting

    Which research topics does ProteoTech (United States) publish most on?

    By volume: Alzheimer's disease research and treatments, Cholinesterase and Neurodegenerative Diseases, 14-3-3 protein interactions and Computational Drug Discovery Methods.

    Alzheimer's disease rese…3Alzheimer's disease research and treatments: 3 fractional worksCholinesterase and Neurodegenerative Diseases: 2 fractional works14-3-3 protein interactions: 1 fractional worksComputational Drug Discovery Methods: 1 fractional worksNuclear Receptors and Si…1Nuclear Receptors and Signaling: 1 fractional worksParkinson's Disease Mechanisms and Treatments: 0 fractional worksAutism Spectrum Disorder Research: 0 fractional worksEnzyme Production and Characterization: 0 fractional worksChemical synthesis and alkaloids: 0 fractional worksCerebrovascular and genetic disorders: 0 fractional works
    PhysiologyPharmacologyMolecular BiologyComputational Theory and Mathematics5 others

    Area is fractional works; colour is the subfield each topic belongs to.

    1. 1 Alzheimer's disease research and treatments Physiology 3 works
    2. 2 Cholinesterase and Neurodegenerative Diseases Pharmacology 2 works
    3. 3 14-3-3 protein interactions Molecular Biology 1 works
    4. 4 Computational Drug Discovery Methods Computational Theory and Mathematics 1 works
    5. 5 Nuclear Receptors and Signaling Cellular and Molecular Neuroscience 1 works
    6. 6 Parkinson's Disease Mechanisms and Treatments Neurology 0 works
    7. 7 Autism Spectrum Disorder Research Cognitive Neuroscience 0 works
    8. 8 Enzyme Production and Characterization Biotechnology 0 works
    9. 9 Chemical synthesis and alkaloids Organic Chemistry 0 works
    10. 10 Cerebrovascular and genetic disorders Neurology 0 works

    How open and international is its research?

    Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

    openly available6.0%not open94.0%

    World: 40% of research is openly available.

    with international co-authors3.4%domestic only96.6%

    World: 18% is written across borders.

    How has ProteoTech (United States)'s research output changed?

    Output in 2022-2025 was 100% lower than in 2018-2021.

    200520102015
    grewheldshrank

    The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

    Other research institutions in Kirkland

    All research institutions in Kirkland

    Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

    Discussion

    Ask a question or share a note about ProteoTech (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.